Front Row Advisors LLC Relmada Therapeutics, Inc. Transaction History
Front Row Advisors LLC
- $271 Million
- Q3 2024
A detailed history of Front Row Advisors LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Front Row Advisors LLC holds 6 shares of RLMD stock, worth $2. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6
Previous 6
-0.0%
Holding current value
$2
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding RLMD
# of Institutions
81Shares Held
12.3MCall Options Held
229KPut Options Held
138K-
Franklin Resources Inc San Mateo, CA1.3MShares$468,7740.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$452,4130.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.19MShares$427,1220.01% of portfolio
-
Parsons Capital Management Inc1MShares$360,9700.21% of portfolio
-
Palo Alto Investors LP Palo Alto, CA732KShares$263,6640.33% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $10.3M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...